血清趋化素与2型糖尿病患者骨密度水平的相关性研究

发布时间：2018-06-17 23:45

本文选题：糖尿病 + 型　；参考：《中国糖尿病杂志》2016年02期

【摘要】：目的探讨血清趋化素(Chemerin)水平与T2DM患者骨密度(BMD)及相关因素的关系。方法选取T2DM患者167例,根据WHO骨质疏松诊断标准分为骨量正常组、骨量减少组和骨质疏松组,另选取健康对照(NC)组36名,测量并记录患者临床一般资料及生化指标,检测血清Chemerin、IL-6及TNF-α水平。结果骨质疏松组血清Chemerin[(89.6±12.1)vs(64.7±13.6)ng/ml]、血清炎症因子TNF-α[(15.6±8.6)vs(4.7±3.3)pg/ml]和IL-6[(7.8±3.5)vs(2.2±0.8)pg/ml]水平高于骨量正常组(P0.05)。血清Chemerin水平与病程、HbA1c、BMI、TNF-α呈正相关(r=0.310、0.350、0.760、0.450,P0.05),与腰椎骨密度(BMD L1~4)呈负相关(r=-0.460,P0.05)。多元线性回归分析显示,Chemerin是T2DM患者BMD L1~4的独立影响因素。结论炎症是糖尿病骨质疏松的重要病理生理过程,Chemerin可能通过调控炎症反应参与骨代谢过程,从而促进骨质疏松的发生。
[Abstract]:Objective to investigate the relationship between serum chemoattractant (Chemerin) level and bone mineral density (BMD) and related factors in patients with T2DM. Methods 167 patients with T2DM were selected and divided into normal group of bone mass, osteopenia group and osteoporosis group, and 36 healthy control group (NC) group according to the diagnostic criteria of WHO osteoporosis, and the general clinical data and biochemical index were measured and recorded. Results the serum levels of Chemerin, IL-6 and TNF- alpha were measured. Results the serum levels of Chemerin[(89.6 + 12.1) vs (64.7 + 13.6) ng/ml], serum inflammatory factor TNF- alpha (15.6 + 8.6) vs (4.7 + 3.3) pg/ml] and IL-6[(7.8 + 3.5) vs (2.2 + 0.8) were higher than the normal group. =0.310,0.350,0.760,0.450, P0.05) and lumbar bone density (BMD L1~4) have a negative correlation (r=-0.460, P0.05). Multivariate linear regression analysis shows that Chemerin is an independent factor of BMD L1~4 in T2DM patients. Conclusion inflammation is an important pathophysiological process of osteoporosis in diabetes. Chemerin may participate in bone metabolism by regulating inflammatory reactions. It promotes the occurrence of osteoporosis.
【作者单位】：江苏大学附属医院核医学科;
【基金】：国家自然科学基金(81370889) 镇江市卫生科技重点项目(SH2013075)
【分类号】：R587.1;R580

【相似文献】